ProMMP-2: TIMP-1 Complexes Identified in Plasma of Healthy Individuals

REFERENCES

• Overall C. M., Kleifeld O. Tumour microenvironment—opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 2006; 6: 227–239
   PubMed Web of Science ®Google Scholar
• Zucker S., Doshi K., Cao J. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: potential clinical applications. Adv. Clin. Chem. 2004; 38: 37–85
   PubMed Web of Science ®Google Scholar
• Nagase H., Woessner F. Matrix metalloproteinases. J. Biol. Chem. 1999; 274: 21491–4
   PubMed Web of Science ®Google Scholar
• Zucker S., Pei D., Cao J., Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). Cell Surface Proteases, S. Zucker, W-T Chen. Academic Press. 2003; 1–74
   Google Scholar
• Birkedal-Hansen H., Moore W. G.I., Bodden M. K., Windsor L. J., Birkedal-Hansen B., DeCarlo A., Engler J. A. Matrix metalloproteinases: a review. Crit. Rev. Oral Biol. Med. 1993; 42: 197–250
   Google Scholar
• Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 2000; 1477: 267–83
   PubMed Web of Science ®Google Scholar
• Fridman R., Fuerst T., Bird R. E., Hoyhtya M., Oelkuct M., Kraus S., Korarek D., Liotta L. A., Berman M. L., Stetler-Stevenson W. G. Domain structure of human 72-kDa gelatinase/type IV collagenase. J. Biol. Chem. 1992; 267: 15398–405
   PubMed Web of Science ®Google Scholar
• Wilhelm S. M., Collier I. E., Marmer B. L., Eisen A. Z., Grant G. A., Goldberg G. I. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal macrophages. J. Biol. Chem. 1989; 264: 17213–22
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson W. G., Krutzsch H. C., Liotta L. A. Tissue inhibitor of metalloproteinase (TIMP-2). J. Biol. Chem. 1989; 264: 17374–8
   PubMed Web of Science ®Google Scholar
• Howard E. W., Bullen E. C., Banda M. J. Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinases-2. J. Biol. Chem. 1991; 266: 13064–9
   PubMed Web of Science ®Google Scholar
• Kleiner D. E., Tuuttila A., Tryggvason K., Stetler-Stevenson W. G. Stability analysis of latent and activated 72-kDa Type IV collagenase: The role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochemistry 1993; 32: 1583–92
   PubMed Web of Science ®Google Scholar
• Goldberg G. I., Marmer B. L., Grant G. A., Eisen A. Z., Wilhelm S., He C. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteinases designated TIMP-2. Proc. Natl. Acad. Sci. 1989; 86: 8207–11
   PubMed Web of Science ®Google Scholar
• Morgunova E. A.T., Bergmann U., Isupov M., Lindqvist Y., Schneider G., Tryggavason K. Structure of human pro-matrix metalloproteinease-2: activation mechanism revealed. Science 1999; 284: 1667–70
   PubMed Web of Science ®Google Scholar
• Kleiner D. E., Unsworth E. D., Krutzsch H. C., Stetler-Stevenson W. G. Higher-order complex formation between the 72 -kilodalton type IV collageanse and tissue inhibitor of metalloproteinases-2. Biochemistry 1992; 31: 1665–72
   PubMed Web of Science ®Google Scholar
• Ward R. V., Hembry R. M., Reynolds J. J., Murphy G. The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Biochem. J. 1991; 278: 179–87
   PubMed Web of Science ®Google Scholar
• Bacon M. C., von Wyl V., Alden C., Sharp G., Robison E., Hessol N., Gange S., Barranday Y., Holman S., Weber K., Young M. A. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin. Diagn. Lab. Immunol. 2005; 12: 1013–9
   PubMedGoogle Scholar
• Zucker S., Conner C., DiMassimo B. I., Ende H., Drews M., Seiki M., Bahou W. F. Thrombin induces the activation of progelatinase A in vascular endothelial cells: physiologic regulation of angiogenesis. J. Biol. Chem. 1995; 270: 23730–8
   PubMed Web of Science ®Google Scholar
• Crabbe T., Zucker S., Cockett M. I., Willenbrook F., Tickle S., O’Connell J. P., Scothern J. M., Murphy G., Docherty A. J.P. Mutation of the active site of glutamic acid gelatinase A: effects of latency, catalysis and binding of tissue inhibitor of metalloproteinases-1 (TIMP-1). Biochemistry 1994; 33: 6684–90
   PubMed Web of Science ®Google Scholar
• Shen B., Shimmon S., Smith M. M., P.G. Biosensor analysis of the molecular interactions of pentosan polysulfate and of sulfated glycosaminoglycans with immobilized elastase, hyaluronidase and lysozyme using surface plasmon resonance (SPR) technology. J. Pharm. Biomed. Anal. 2003; 31: 83–93
   PubMed Web of Science ®Google Scholar
• Olson M. W., Gervasi D. C., Mobashery S., Fridman R. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J. Biol. Chem. 1997; 272: 29975–83
   PubMed Web of Science ®Google Scholar
• Moutsiakis D., Mancuso P., Krutzsch H., Stetler-Stevenson W., Zucker S. Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connect. Tissue Res. 1992; 28: 213–30
   PubMed Web of Science ®Google Scholar
• Price S. J., Greaves D. R., Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene. Role of Sp1 in allele-specific transcriptional regulation. J. Biol. Chem. 2001; 276: 7549–58
   PubMed Web of Science ®Google Scholar
• Nackley A. G., Shabalina S. Z., Tchivileva I. E., Satterfield K., Korchynskyi O., Makarov S. S., Maixner W., Diatchenko L. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006; 314: 1930–3
   PubMed Web of Science ®Google Scholar
• Parmley J. L., Hurst L. D. How do synonymous mutations affect fitness?. BioEssays 2007; 29: 515–9
   PubMed Web of Science ®Google Scholar
• Shen L. X., Basilion J. P., Stanton V. P., Jr. Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc. Natl. Acad. Sci. 1999; 96: 7871–6
   PubMed Web of Science ®Google Scholar
• Morgunova E., Tuuttila A., Bergmann U., Tryggvasson K. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc. Natl. Acad. Sci. 2002; 99: 7414–9
   PubMed Web of Science ®Google Scholar